ライフサイエンスコーパス: XDR-TB

1 Mortality was higher among XDR-TB cases than among MDR-TB cases (PR, 1.82; 95% CI,

2 exogenous reinfection as a cause of MDR and XDR TB in these settings has not been determined.

3 e [ST] 34 and ST 60, associated with MDR and XDR TB, respectively) were responsible for 85% of reinfe

4 ant mechanism for the development of MDR and XDR TB.

5 needed to reduce the transmission of MDR and XDR TB.

6 33799) tested a 6-month treatment of MDR and XDR-TB consisting of high-dose linezolid, bedaquiline, a

7 MDR and XDR-TB isolates were significantly more likely to belong

8 sequent multiple emergence events of MDR and XDR-TB particularly involving the Lisboa3 clade.

9 e to first- and second-line drugs in MDR and XDR-TB.

10 ion, transmission, and evolution of MDR- and XDR-TB in Belarus and will enable improved diagnostics,

11 enetic composition and evolution of MDR- and XDR-TB in the region, we sequenced and analyzed the geno

12 utionary history is compatible with MDR- and XDR-TB originating in Portugal in the 70's and 80's, res

13 atives for molecular diagnostics of MDR- and XDR-TB.

14 provides ideal conditions for an MDR-TB and XDR-TB epidemic of unparalleled magnitude.

15 ignificant difference between the MDR-TB and XDR-TB groups (p > 0.05).

16 and more nodules of 10 mm in the MDR-TB and XDR-TB groups, respectively.

17 easures necessary for controlling MDR-TB and XDR-TB in this context.

18 ch underly 64.2% and 94.0% of all MDR-TB and XDR-TB isolates, respectively.

19 tomography (CT) scan findings of MDR-TB and XDR-TB patients.

20 sful response to the emergence of MDR-TB and XDR-TB will necessitate increased resources for and coll

21 nts were divided into two groups (MDR-TB and XDR-TB) based on two types of drug resistance.

22 tremely drug resistant organisms (MDR-TB and XDR-TB).

23 sis, management and prevention of MDR-TB and XDR-TB, especially at the primary care physician level.

24 vely drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) has intensified the critical publi

25 CT characteristics overlap between XDR-TB and those with MDR-TB.

26 luated the accuracy of the Akonni Biosystems XDR-TB (extensively drug-resistant TB) TruArray and late

27 luated the accuracy of the Akonni Biosystems XDR-TB TruArray and lateral-flow cell (XDR-LFC), a novel

28 Compared with MDR-TB cases, XDR-TB cases were more likely to have disseminated TB di

29 associated with resistance to drugs defining XDR TB.

30 nce of multi- (MDR-TB) and extensively-drug (XDR-TB) resistant Mycobacterium tuberculosis strains pos

31 ves: To propose an up-to-date definition for XDR-TB.

32 Our approach could enable testing for XDR-TB in point-of-care settings, potentially identifyin

33 sively drug-resistant (XDR), and 3 (21%) had XDR TB.

34 and count of individuals with RR-TB that had XDR-TB and pre-XDR-TB across the province and in Cape To

35 uth Africa between 2012 and 2015 to identify XDR-TB and pre-XDR-TB (RR-TB with resistance to one seco

36 quencing and dating analysis to determine if XDR-TB had emerged recently or had ancient antecedents.

37 We collected M/XDR TB isolates from regions of high TB burden in India,

38 assessment of PZA molecular diagnostics in M/XDR TB cases.

39 -/extensively drug-resistant tuberculosis (M/XDR TB), but large studies of mutations as markers of re

40 specificities of mutations associated with M/XDR TB to inform the development of rapid diagnostic met

41 d M. tuberculosis resistance mutations and M/XDR-TB treatment outcomes, limiting our current ability

42 es the successful introduction of new anti-M/XDR-TB antibiotic regimens.

43 al M. tuberculosis isolates from a diverse M/XDR-TB patient population at three high-burden clinical

44 duration of anti-TB therapy, treatment of M/XDR-TB is very expensive and often associated with adver

45 rization of the evolutionary trajectory of M/XDR-TB strains in Portugal, spanning a time-period of tw

46 ng and uncontrolled recent transmission of M/XDR-TB, predominantly associated with the Lisboa3 and Q1

47 sistant and extensively drug-resistant TB (M/XDR-TB).

48 vely drug-resistant tuberculosis (XDR-TB) (M/XDR-TB).

49 Some patients with M/XDR-TB may have to be treated with currently available a

50 tment for TB, especially for patients with M/XDR-TB, would be highly desired.

51 eve cure for the majority of patients with M/XDR-TB.

52 n-synonymous mutations predominantly in MDR-/XDR-TB strains with predicted protein destabilising effe

53 al importance in predicting whether the MDR-/XDR-TB epidemic will be sustained across the human popul

54 use of bedaquiline for the treatment of MDR/XDR TB.

55 use of bedaquiline for the treatment of MDR/XDR TB.

56 A total of 83 cases of XDR-TB were reported in the United States from 1993 to 2

57 Control of XDR-TB will require additional interventions, the impact

58 he percentage of pre-XDR-TB and the count of XDR-TB/pre-XDR-TB highly heterogeneous with geographic h

59 ions: Our study supports a new definition of XDR-TB as MDR-TB and additional resistance to FQ plus be

60 treatment and thus putting the definition of XDR-TB into question.

61 rapid, automated assay for the detection of XDR-TB plus resistance to the drug isoniazid (INH) for p

62 required to understand underlying drivers of XDR-TB transmission in these locations.

63 It is unclear whether the emergence of XDR-TB in KwaZulu-Natal was due to recent inadequacies i

64 he aminoglycoside kanamycin is a hallmark of XDR-TB.

65 Estimated incidence of XDR-TB hospitalizations was 7.2 per 100,000 health care

66 The number of XDR-TB cases declined from 18 (0.07% of 25 107 TB cases)

67 identified 23 patients who developed MDR or XDR TB after being treated for less resistant TB between

68 lture-positive TB who later developed MDR or XDR TB in Tugela Ferry, KwaZulu-Natal, South Africa duri

69 ely to be hospitalized with either MDR-TB or XDR-TB than were non-health care workers.

70 than non-health care workers with MDR-TB or XDR-TB were women (78% vs. 47%; P < 0.001), and health c

71 least MDR-TB (483/732; 66.0%), and potential XDR-TB genotypic resistance was observed (3/732; 0.4%),

72 een 2012 and 2015 to identify XDR-TB and pre-XDR-TB (RR-TB with resistance to one second-line drug) s

73 dividuals with RR-TB that had XDR-TB and pre-XDR-TB across the province and in Cape Town, as well as

74 BPaL-based regimens for MDR/RR-TB and pre-XDR-TB are safe and highly effective in non-trial settin

75 R-TB and 0.2% and 0.4%, respectively, in pre-XDR-TB/XDR-TB populations.

76 We found the percentage of pre-XDR-TB and the count of XDR-TB/pre-XDR-TB highly heterog

77 nd 1% in pre-extensively drug-resistant (pre-XDR-TB)/XDR-TB populations.

78 B and pre-extensively drug-resistant TB (pre-XDR-TB) initiated on BPaL-based regimens in Belarus and

79 Pre-extensively drug-resistant TB (pre-XDR-TB) refers to MDR/RR-TB that is also resistant to a

80 ge of pre-XDR-TB and the count of XDR-TB/pre-XDR-TB highly heterogeneous with geographic hotspots wit

81 cin and 90.4% (207/229) of patients with pre-XDR-TB treated with BPaL plus clofazimine.

82 one, expanded culture and DST did not reduce XDR-TB incidence, but they enhanced the impact of transm

83 work shows that interventions used to reduce XDR-TB incidence may need to be targeted within spatial

84 s in six genes predicted clinically relevant XDR-TB phenotypes with 90 to 98% sensitivity and almost

85 Twenty-six XDR-TB cases (35%) died during treatment, of whom 21 (81

86 Sixteen isolates from six suspected XDR-TB cases were sequenced; five cases were analyzed in

87 uinolone, and extensively drug-resistant TB (XDR-TB) isolates are additionally resistant to other key

88 (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains have further worsened the TB pandemic.

89 (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains.

90 pre-extensively drug-resistant (pre-XDR-TB)/XDR-TB populations.

91 12 was found to be active against the tested XDR-TB strains and orally active in the serum inhibition

92 e times within each cluster, indicating that XDR TB is currently not widely transmitted.

93 luding the timing of acquisitions leading to XDR-TB in the LAM4 spoligotype, and to calculate the num

94 loxacin-resistant TB hotspots was similar to XDR-TB hotspots, suggesting that fluoroquinolone-resista

95 a sympatric evolutionary trajectory towards XDR-TB with the potential for global reach.

96 tibiotics are used as a last resort to treat XDR-TB.

97 y drug-resistant Mycobacterium tuberculosis (XDR-TB) encountered at a London teaching hospital betwee

98 and extensively drug-resistant tuberculosis (XDR-TB) (M/XDR-TB).

99 in extensively drug-resistant tuberculosis (XDR-TB) and HIV co-infected patients in South Africa.

100 ith extensively drug-resistant tuberculosis (XDR-TB) are also resistant to all types of fluoroquinolo

101 and extensively drug resistant tuberculosis (XDR-TB) cases, there is an urgent need for new drugs wit

102 of extensively drug-resistant tuberculosis (XDR-TB) has raised global public health concern, given t

103 of extensively drug-resistant tuberculosis (XDR-TB) strains are also PZA resistant.

104 20, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB with resistance to rifampicin

105 to extensively drug-resistant tuberculosis (XDR-TB).

106 Although the number of US XDR-TB cases has declined since 1993, coinciding with im

107 olution of resistance within patients, while XDR-TB was acquired through both routes.

108 9 y (34.6, 35.2) assuming only patients with XDR TB received bedaquiline.

109 ld-type and mutant sequences associated with XDR-TB directly from sputum.

110 ion in prisons, some involving isolates with XDR-TB, and mutations linked to third-line drug bedaquil

111 CT scan findings in patients with XDR-TB are similar to those of patients with MDR-TB for

112 However, patients with XDR-TB tend to have more parenchymal calcification and l

113 Among patients with XDR-TB, compared with persons receiving no group A drug,